These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 10809428)
1. Role of antigenemia assay in the early diagnosis and treatment of CMV infection in renal transplant patients. Chiaramonte S; Pellizzer G; Rassu M; Dissegna D; Bragantiini L; Zuccarotto D; La Greca G Clin Nephrol; 2000 Apr; 53(4):suppl 10-2. PubMed ID: 10809428 [TBL] [Abstract][Full Text] [Related]
2. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation]. Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863 [TBL] [Abstract][Full Text] [Related]
3. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation. Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893 [TBL] [Abstract][Full Text] [Related]
4. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717 [TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
7. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients. Piiparinen H; Helanterä I; Lappalainen M; Suni J; Koskinen P; Grönhagen-Riska C; Lautenschlager I J Med Virol; 2005 Jul; 76(3):367-72. PubMed ID: 15902704 [TBL] [Abstract][Full Text] [Related]
9. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628 [TBL] [Abstract][Full Text] [Related]
10. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400 [TBL] [Abstract][Full Text] [Related]
12. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Bacigalupo A; Tedone E; Sanna MA; Moro F; Van Lint MT; Grazi G; Balestreri M; Frassoni F; Occhini D; Gualandi F Haematologica; 1992; 77(6):507-13. PubMed ID: 1337746 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients. Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622 [TBL] [Abstract][Full Text] [Related]
14. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review. Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578 [TBL] [Abstract][Full Text] [Related]
16. [Primary cytomegalovirus infection after combined cadaveric transplantation of the liver and kidney]. Slavicek J; Puretić Z; Glavas-Boras S; Smalcelj R; Barisić I; Vuković J; Seso-Simić D; Slavicek V; Humar I; Kes P Acta Med Croatica; 2003; 57(1):87-90. PubMed ID: 12876872 [TBL] [Abstract][Full Text] [Related]
17. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819 [TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Vlieger AM; Boland GJ; Jiwa NM; de Weger RA; Willemze R; de Gast GC; Falkenburg JH Bone Marrow Transplant; 1992 Apr; 9(4):247-53. PubMed ID: 1318141 [TBL] [Abstract][Full Text] [Related]
20. Is combined pretransplantation seropositivity of kidney transplant recipients for cytomegalovirus antigens (pp150 and pp28) a predictor for protection against infection? Essa S; Pacsa A; Said T; Nampoory MR; Raghupathy R; Johny KV; Al-Nakib W; Al-Mosawy M Med Princ Pract; 2008; 17(1):66-70. PubMed ID: 18059104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]